文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

吸入型双特异性单域抗体对 SARS-CoV-2 变体的广泛中和作用。

Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody.

机构信息

MOE/NHC/CAMS Key Laboratory of Medical Molecular Virology, Shanghai Institute of Infectious Disease and Biosecurity, The Fifth People's Hospital of Shanghai, Institutes of Biomedical Sciences, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.

Shanghai Key Laboratory of Lung Inflammation and Injury, Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China; Shanghai Engineering Research Center for Synthetic Immunology, Shanghai 200032, China.

出版信息

Cell. 2022 Apr 14;185(8):1389-1401.e18. doi: 10.1016/j.cell.2022.03.009. Epub 2022 Mar 10.


DOI:10.1016/j.cell.2022.03.009
PMID:35344711
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8907017/
Abstract

The effectiveness of SARS-CoV-2 vaccines and therapeutic antibodies have been limited by the continuous emergence of viral variants and by the restricted diffusion of antibodies from circulation into the sites of respiratory virus infection. Here, we report the identification of two highly conserved regions on the Omicron variant receptor-binding domain recognized by broadly neutralizing antibodies. Furthermore, we generated a bispecific single-domain antibody that was able to simultaneously and synergistically bind these two regions on a single Omicron variant receptor-binding domain as revealed by cryo-EM structures. We demonstrated that this bispecific antibody can be effectively delivered to lung via inhalation administration and exhibits exquisite neutralization breadth and therapeutic efficacy in mouse models of SARS-CoV-2 infections. Importantly, this study also deciphered an uncommon and highly conserved cryptic epitope within the spike trimeric interface that may have implications for the design of broadly protective SARS-CoV-2 vaccines and therapeutics.

摘要

SARS-CoV-2 疫苗和治疗性抗体的有效性受到病毒变异的不断出现以及抗体从循环系统扩散到呼吸道病毒感染部位的限制。在这里,我们报告了两种在 Omicron 变异受体结合域上高度保守的区域的鉴定,这些区域被广泛中和抗体所识别。此外,我们生成了一种双特异性单域抗体,该抗体能够在冷冻电镜结构中同时协同结合单个 Omicron 变异受体结合域上的这两个区域。我们证明,这种双特异性抗体可以通过吸入给药有效地递送到肺部,并在 SARS-CoV-2 感染的小鼠模型中表现出出色的中和广度和治疗效果。重要的是,这项研究还揭示了刺突三聚体界面内一个罕见且高度保守的隐藏表位,这可能对设计广泛保护的 SARS-CoV-2 疫苗和治疗方法具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/eb5299e2de82/figs7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/91921f313ba0/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/299e87850f9c/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/478947ac66fb/figs1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/ac889e23fa0e/figs2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/a64520bff288/figs3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/92c738afc66e/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/af819b6bfc41/figs4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/3527d6ebddfb/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/5983dc473a68/figs5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/c453dad92cca/figs6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/ead6264d32d4/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/665949210b77/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/f389f11cd301/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/da8f5652ebd2/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/eb5299e2de82/figs7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/91921f313ba0/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/299e87850f9c/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/478947ac66fb/figs1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/ac889e23fa0e/figs2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/a64520bff288/figs3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/92c738afc66e/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/af819b6bfc41/figs4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/3527d6ebddfb/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/5983dc473a68/figs5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/c453dad92cca/figs6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/ead6264d32d4/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/665949210b77/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/f389f11cd301/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/da8f5652ebd2/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/589a/8907017/eb5299e2de82/figs7_lrg.jpg

相似文献

[1]
Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody.

Cell. 2022-4-14

[2]
Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.

J Virol. 2022-8-24

[3]
A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.

J Virol. 2022-9-14

[4]
Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants.

Antiviral Res. 2023-4

[5]
A novel bispecific antibody targeting two overlapping epitopes in RBD improves neutralizing potency and breadth against SARS-CoV-2.

Emerg Microbes Infect. 2024-12

[6]
Neutralizing Ability of a Single Domain VNAR Antibody: In Vitro Neutralization of SARS-CoV-2 Variants of Concern.

Int J Mol Sci. 2022-10-14

[7]
Human antibody BD-218 has broad neutralizing activity against concerning variants of SARS-CoV-2.

Int J Biol Macromol. 2023-2-1

[8]
High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.

Microbiol Spectr. 2021-12-22

[9]
Superimmunity by pan-sarbecovirus nanobodies.

Cell Rep. 2022-6-28

[10]
Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern.

Front Immunol. 2022

引用本文的文献

[1]
Antigenic and mutational insights into the Nipah virus G glycoprotein: implications for viral entry, host specificity, therapeutics, and vaccine development.

PeerJ. 2025-8-12

[2]
Inhaled bispecific single-domain antibody BM219 for mild-to-moderate COVID-19: a double-blind, randomized, placebo-controlled phase 2 trial.

Cell Discov. 2025-7-17

[3]
Topical delivery of a human single-domain antibody targeting IL-33 to inhibit mucosal inflammation.

Cell Mol Immunol. 2025-6-11

[4]
Construction and application of a large capacity VNAR library from the whitespotted bamboo shark ().

Acta Pharm Sin B. 2025-4

[5]
Nanobodies: From Discovery to AI-Driven Design.

Biology (Basel). 2025-5-14

[6]
Small but Mighty: Nanobodies in the Fight Against Infectious Diseases.

Biomolecules. 2025-4-23

[7]
Identification of a nanobody able to catalyze the destruction of the spike-trimer of SARS-CoV-2.

Front Med. 2025-5-3

[8]
Nanoscale warriors against viral invaders: a comprehensive review of Nanobodies as potential antiviral therapeutics.

MAbs. 2025-12

[9]
Identification and characterization of a broadly neutralizing and protective nanobody against the HA1 domain of H5 avian influenza virus hemagglutinin.

J Virol. 2025-5-20

[10]
Application of pre-amplification-based CRISPR-Cas nanostructured biosensors for bacterial detection.

Nanomedicine (Lond). 2025-4

本文引用的文献

[1]
SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex.

Science. 2022-2-18

[2]
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2.

Nature. 2022-2

[3]
Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.

Nature. 2022-2

[4]
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.

Nature. 2022-2

[5]
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.

Nature. 2022-2

[6]
Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.

Lancet. 2022-1-15

[7]
A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants.

Signal Transduct Target Ther. 2021-11-3

[8]
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study.

Science. 2021-10-22

[9]
Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy.

Nature. 2021-11

[10]
Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy.

Immunity. 2021-9-14

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索